Orgenesis
Orgenesis is a biotechnology company that has developed the POCare Platform to make cell and gene therapies more accessible and affordable through a globally harmonized and decentralized manufacturing infrastructure.
Orgenesis POCare Platform
The POCare Platform by Orgenesis is tailored to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format. Designed to lower costs and support high-quality, standardized CGTs, the platform consists of three core components: Therapies, Technologies, and Network. This integrated solution aims to tackle logistical complexities and expedite the scale-out of advanced therapies, regardless of patient location.
Orgenesis Mobile Processing Units and Labs™
Orgenesis Mobile Processing Units and Labs™ (OMPUL™) are self-contained, all-in-one bioprocessing units. These units integrate seamlessly into the Orgenesis POCare Platform, offering a streamlined pathway for CGT manufacturing. Their closed-loop design ensures efficiency and standardization, facilitating decentralized production of advanced therapies directly at the point of care
Global POCare Network
Orgenesis' POCare Network is a global alliance connecting academia, research institutions, and hospitals. This network enables the development, production, and distribution of advanced therapies at the point of care. By providing a harmonized pathway to commercialize these treatments, the network significantly enhances the reach and impact of Orgenesis' CGT solutions.
Pipeline of Advanced Therapies
Orgenesis maintains a diverse pipeline of advanced therapies in various stages of development. This includes therapies for immuno-oncology, viral diseases, metabolic and autoimmune diseases, vascular and musculoskeletal diseases, and kidney disease. The pipeline is supported through partnerships with early-stage biotechnology developers and includes preclinical studies, IND enabling studies, clinical trials, and clinical use.
Headquarters and Global Presence
Orgenesis is headquartered at 20271 Goldenrod Lane, Germantown, MD 20876, USA. The company operates globally with development and service centers in the United States, Belgium, Israel, and South Korea. This international presence underpins Orgenesis' commitment to making advanced therapies accessible worldwide.